ESMO Open · 2021 · 12 citations · 18 references
MedicineMolecular GeneticsPathologyMolecular OncologyNeoplasiaTranscriptomicsCancer Molecular PathologyGenetic HeterogeneityIntertumoral HeterogeneityIntratumoral HeterogeneityMolecular Tumor ProfilingTranscriptomic HeterogeneityBraf V600 MutationsCancer Heterogeneity AnalysisColorectal Cancer PathologyConsensus Molecular SubtypesIntra-tumor HeterogeneityIntratumor Genetic HeterogeneityIntratumor HeterogeneityTumor Heterogeneity Assessment
BACKGROUND: Intratumor heterogeneity (ITH) is described as the presence of various clones within one tumor, each with their own unique features in terms of morphology, inflammation, genetics or transcriptomics. Heterogeneity provides the fuel for drug resistance; therefore, an accurate assessment of tumor heterogeneity is essential for the development of effective therapies. The purpose of this study was to dissect morphologic and molecular ITH in colorectal adenocarcinoma. MATERIALS AND METHODS: BRAFmt) consecutive metastatic colorectal adenocarcinomas was assessed for morphologic heterogeneity. The two heterogeneous components of each specimen underwent a histopathological, immunohistochemical and molecular characterization to evaluate: histologic variant, grading, tumor-infiltrating lymphocytes (TILs), mismatch repair proteins' expression, KRAS/BRAF/NRAS mutations, microsatellite instability (MSI) status and consensus molecular subtype (CMS). RESULTS: BRAFmt primary colorectal adenocarcinomas presented a heterogeneous morphology. Among these, eight cases had adequate material for molecular profiling. Five out of the eight (62.5%) cases resulted instable at MSI testing. The majority (62.5%) of the samples showed a CMS4 phenotype based on gene expression profiling. Heterogeneity in CMS classification was observed in four out of eight cases. One out of eight cases presented significant heterogeneity in the number of TILs between the two components of the tumor. CONCLUSIONS: BRAFmt adenocarcinoma cases in our small series and might contribute to variability in response to anticancer therapy and clinical outcomes. Assessment of morphological and molecular ITH is needed to improve colorectal cancer classification and to tailor anticancer treatments and should be included in the pathology report.
18
The consensus molecular subtypes of colorectal cancer
Justin Guinney, Rodrigo Dienstmann, Xin Wang et al. · Nature Medicine · 2015 · 5.3K citations · Full text
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
Thierry André, Kai‐Keen Shiu, Tae Won Kim et al. · New England Journal of Medicine · 2020 · 3K citations · Full text
Medicine, Oncology, Pharmacology +17
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
Scott Kopetz, Axel Grothey, Rona Yaeger et al. · New England Journal of Medicine · 2019 · 1.5K citations · Full text
Medicine, Oncology, Pharmacology +17
A Big Bang model of human colorectal tumor growth
Andrea Sottoriva, Haeyoun Kang, Zhicheng Ma et al. · Nature Genetics · 2015 · 1.1K citations
Medicine, Cancer Biology, Oncology +14